GUIZHOU YIBAI PHARMACEUTICAL CO., LTD. |
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 4.16 CNY | -.--% |
|
+3.23% | -26.89% |
| 04-18 | Guizhou Yibai Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 2023 | YiBai Pharma to Repurchase Up to 40 Million Yuan Shares | MT |
| Sales 2022 | 2.74B 378M 30.11B | Sales 2023 | 2.82B 390M 31.05B | Capitalization | 4.51B 622M 49.61B |
|---|---|---|---|---|---|
| Net income 2022 | -426M -58.84M -4.69B | Net income 2023 | 103M 14.23M 1.13B | EV / Sales 2022 | 1.78 x |
| Net Debt 2022 | 495M 68.32M 5.45B | Net Debt 2023 | 301M 41.54M 3.31B | EV / Sales 2023 | 1.7 x |
| P/E ratio 2022 |
-10.3
x | P/E ratio 2023 |
43.4
x | Employees | 5,509 |
| Yield 2022 * |
-
| Yield 2023 |
1.16% | Free-Float | 68.33% |
More Fundamentals
* Assessed data
More news
| 1 week | +3.23% | ||
| 1 month | -15.27% | ||
| 3 months | -5.45% | ||
| 6 months | -27.53% | ||
| Current year | -26.89% |
1 week
4.01
4.19
1 month
3.774.92
Current year
3.775.94
1 year
3.776.35
3 years
3.778.80
5 years
3.778.80
10 years
3.7737.68
| Managers | Title | Age | Since |
|---|---|---|---|
Ya Qi Dou
CEO | Chief Executive Officer | 40 | 30/04/08 |
Xian Hong Jiang
DFI | Director of Finance/CFO | 39 | 22/03/20 |
Zhi Wei Wang
BRD | Director/Board Member | 54 | 20/02/11 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
Qi Ling Dou
FOU | Founder | 64 | 31/05/95 |
Zhi Wei Wang
BRD | Director/Board Member | 54 | 20/02/11 |
Ya Qi Dou
CEO | Chief Executive Officer | 40 | 30/04/08 |
| Date | Price | Change | Volume |
|---|---|---|---|
| 30/04/24 | 4.16 | -.--% | 11,189,600 |
| 29/04/24 | 4.16 | +3.23% | 11,061,900 |
End-of-day quote Shanghai S.E., April 29, 2024
More quotes
GUIZHOU YIBAI PHARMACEUTICAL CO., LTD is a China-based company, principally engaged in the production and distribution of pharmaceuticals. The Company provides prescription drugs and over the counter (OTC) products, including injections, capsules, oral liquid, granules and tablets, among others. The company's products are applied in the treatment of cancer, cardiovascular and cerebrovascular, orthopedics, digestion, gynecology, children and breathing, among others. The Company mainly conducts its businesses within domestic markets.
Sector
Pharmaceuticals
Calendar
10/05/2024
- Annual General Meeting
| 1st Jan change | Capi. | |
|---|---|---|
| -26.89% | 455M | |
| +26.08% | 662B | |
| +21.85% | 546B | |
| -4.77% | 359B | |
| +16.97% | 323B | |
| +5.69% | 290B | |
| +13.68% | 234B | |
| +3.65% | 198B | |
| -11.12% | 194B | |
| +8.08% | 167B |
- Stock Market
- Equities
- 600594 Stock
